Document:

<PAGE>

                                  EXHIBIT 10.17

                    CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
                          FOR THE PORTIONS MARKED [***]

                            AGREEMENT BY AND BETWEEN
                           ARENA PHARMACEUTICALS, INC.
                                       AND
                         TAISHO PHARMACEUTICAL CO., LTD.

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>

                                                                                                    Page
                                                                                                    ----
<S>                                                                                                 <C>
Article I.        Definitions                                                                          1

Article II.       Background and Receptor Cloning Research                                             6

Article III.      Arena Activation Technology                                                          7

Article IV.       Research and Development Fees                                                        8

Article V.        License Grant                                                                        9

Article VI.       Screening by Arena                                                                  11

Article VII.      Clinical Development of CART(TM)Identified Compound                                 12

Article VIII.     Marketing Authorization                                                             14

Article IX.       Clinical Development of Subsequent Compounds                                        15

Article X.        Royalty Payments                                                                    17

Article XI.       Payment Arrangement                                                                 18

Article XII.      Confidentiality                                                                     18

Article XIII.     Patent Infringement and Enforcement                                                 19

Article XIV.      Representations and Warranties                                                      20

Article XV.       Indemnity                                                                           21

Article XVI.      Termination                                                                         22

Article XVII.     Relationship of the Parties                                                         22

Article XVIII.    Miscellaneous Provisions                                                            23

Signature Blocks                                                                                      25

</TABLE>

                                 --PLEASE NOTE--

     Provisions Within This Agreement Are Deemed "CONFIDENTIAL" In Accordance
With The Terms of Article XII.

         Reviewers are advised to confirm with their attorney as to any
       obligations and/or requirements regarding review of this Agreement

<PAGE>

                                    AGREEMENT

         This Agreement ("Agreement") is effective as of March 21, 2001
("Effective Date") by and between ARENA PHARMACEUTICALS, INC., having a place of
business at 6166 Nancy Ridge Drive, San Diego, California, 92121 USA ("Arena"),
and TAISHO PHARMACEUTICAL CO., LTD., having a place of business at 24-1, Takata
3-Chome, Toshimaku, Tokyo 170-8633, JAPAN ("Taisho").

         WHEREAS, Taisho is a pharmaceutical company focused on contributing to
the maintenance and improvement of consumer's health by creating and providing
quality drugs, related healthcare products and information services that satisfy
consumers with various lifestyles;

         WHEREAS, Arena is a biopharmaceutical organization focused on the
discovery and development of innovative therapeutics;

         WHEREAS, Arena and Taisho each desire to enter into this Agreement on
the terms and conditions set forth herein.

         NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, Arena and Taisho hereby agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

         Unless otherwise specifically provided herein, the following terms
shall have the following meanings:

"AFFILIATE" when used with reference to a specified person or entity, means any
person or entity directly or indirectly controlling, controlled by or under
common control with the specified person or entity, while "control" in this
context means the direct or indirect ownership of at least 50% of the
outstanding voting securities of a person or entity. For purposes of this
Agreement, "Affiliate" in relationship to Arena excludes BRL Screening, Inc.

"ANNUAL" means the period between January 1 and December 31, inclusive.

"ARENA ACTIVATION TECHNOLOGY" means an Arena proprietary approach, referred to
by Arena as "CART Technology", to identifying, selecting and altering a
region(s) within a G Protein Coupled Receptor that, when altered, leads to or
enhances ligand-independent constitutive activation of the altered receptor.

"ARENA CLONING" means an Arena proprietary approach to cloning of
[****************] by expression cloning from Taisho Cells.

 "ARENA LIBRARY COMPOUNDS" means approximately 80,000 Library Compounds
synthesized by Arena prior to the Effective Date or during the term of this
Agreement, or obtained by Arena from a Third Party prior to the Effective Date
or during the term of this Agreement, excluding: (i) any compound(s) licensed by
Arena to any Third Party prior to Screening of any Taisho Activated Receptor,
and/or (ii) any compound(s) that is the

                                       1
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

subject of any negotiation between Arena and a Third Party prior to Screening
of any Taisho Activated Receptor.

"ARENA PATENT RIGHTS" means all present and/or future patents (including
inventor's certificates) and all present and/or future applications (including
provisional applications) therefor throughout the world as the case may be, and
substitutions, extensions, reissues, renewals, divisions, continuations, or
continuation-in-part thereof or therefor, owned or controlled (either fully or
partially) by Arena, or under which Arena may grant licenses or sublicenses, to
the extent they are directed to (1) Arena Activation Technology applied to
[**************] and/or (2) Arena Cloning applied to [**************] and/or (3)
[**************] and/or (4) Taisho Activated Receptor(s) and/or (5) CART
Identified Compound(s) and/or (6) Drug Product(s) and/or (7) Screening Assay(s).

"ARENA SCREENING" has the same meaning as set forth in Section 6.2(a) of this
Agreement.

"BACK-UP COMPOUND" means, as to Taisho Activated Receptor, a subsequent CART
Identified Compound developed by Taisho and/or Taisho's Licensee(s) subsequently
to the preceding CART Identified Compound precedingly developed for the same or
similar therapeutic indication as the preceding CART Identified Compound, that
is developed after the discontinuation of the development of the preceding CART
Identified Compound or that is reserved at the lower stage of the development
than that of the preceding CART Identified Compound or that is simultaneously
developed with the preceding CART Identified Compound with the intent to
commercialize the subsequent CART Identified Compound only in the event the
development of the preceding CART Identified Compound is discontinued. For the
purpose of determination of such intent, a subsequent CART Identified Compound
shall be deemed Subsequent Compound but not Back-Up Compound if Phase 3 Clinical
Study thereof is started prior to the discontinuation of the development of the
preceding CART Identified Compound.

"BEST REASONABLE COMMERCIAL EFFORTS" means efforts to achieve a designated
objective, which efforts are based upon reasonably prudent business factors and
considerations.

"[**************]" has the same meaning as set forth in Section 2.1 of this
Agreement.

"CART IDENTIFIED COMPOUND(S)" means a compound, and/or a Derivative of a CART
Identified Compound, that has been identified as a modulator of a Taisho
Activated Receptor by Taisho or Taisho's Licensee(s) during the term of this
Agreement or by Arena Screening.

"CONTINUING UTILIZATION FEE" has the same meaning as set forth in Section 5.5 of
this Agreement.

"DERIVATIVE" of a first compound means a compound having the same core structure
as the first compound, that has been synthesized or conceived, and then
subsequently reduced to practice by Taisho, Taisho's Licensee(s) or Arena during
the term of this Agreement.

"DRUG PRODUCT" means a therapeutic product comprising a CART Identified Compound
or a therapeutic product developed by Taisho, Taisho's Licensee(s) or Third
Party working on behalf or in conjunction with Taisho, using any material
identified by Arena in accordance with Article II of this Agreement.

"DRUG PRODUCT REVENUE" [********************************************************
********************************************************************************

                                       2
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

********************************************************************************
********************************************************************************
********************************************************************************
********************************************************************************
********************************************************************************
********************************************************************************
********************************************************************************
********************************************************************************
********************************************************************************
******************************************].

"EFFECTIVE DATE" means the date first above written in this Agreement.

"ENDOGENOUS" means naturally occurring.

"EUROPEAN COUNTRY" means any of the following countries: United Kingdom,
Germany, France, Italy, and Spain.

"FDA" means the United States Food and Drug Administration.

"G PROTEIN COUPLED RECEPTOR" and "GPCR" means an Endogenous cell-surface
receptor defined by having three (3) intracellular loops, three (3)
extracellular loops, an amino terminus and a carboxy terminus.

"INFORMATION" has the same meaning as set forth in Section 12.1 of this
Agreement.

"IND" has the same meaning as set forth in 21 C.F.R. Section 312.20, including
any and all amendments, modifications or changes as may be made thereto in the
future, or the equivalent thereof in any applicable country within the
Territory.

"LIBRARY COMPOUNDS" means chemical compounds.

"MARKETING AUTHORIZATION" means the granting or authorization, by an appropriate
governmental agency, to commercialize a pharmaceutical product; by way of
example, the FDA is an appropriate governmental agency.

"MEASURED RESPONSE" when used in reference to the phrase "Taisho Activated
Receptor" means a signal measured based upon an assay end-point used to assess
the signal.

"NOTICE" has the same meaning as set forth in Section 18.11 of this Agreement.

"PHASE 2 CLINICAL STUDY" has the same meaning as set forth in 21 C.F.R. Section
312.21(b), including any and all amendments, modifications or changes thereto as
may be made thereto in the future, or the equivalent thereof, in any applicable
country within the Territory.

"PHASE 3 CLINICAL STUDY" has the same meaning as set forth in 21 C.F.R. Section
312.21(c), including any and all amendments, modifications or changes thereto as
may be made thereto in the future, or the equivalent thereof, in any applicable
country within the Territory.

                                       3
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

"PARTY" means either Arena or Taisho, as the case may be; "Parties" means both
Arena and Taisho.

"REGULATORY AGENCY" includes, but is not be limited to, FDA, or similar
regulatory bodies in the Territory.

"SCREENING" means the process of contacting a chemical compound with a Taisho
Activated Receptor.

"SCREENING ASSAY" means an Arena assay approach for Screening that has been
validated based upon Successful Screening of a Taisho Activated Receptor.

"SCREENING ASSAY NOTICE" has the same meaning as set forth in Section 3.2 of
this Agreement.

"SCREENING REQUEST" has the same meaning as set forth in Section 6.1 of this
Agreement.

"SUBSEQUENT COMPOUND" means, as to a Taisho Activated Receptor, a subsequent
CART Identified Compound developed by Taisho and/or Taisho's Licensee(s)
subsequently to the preceding CART Identified Compound precedently developed for
the same or similar therapeutic indication as the preceding CART Identified
Compound, that is developed after the receipt of Marketing Authorization for the
preceding CART Identified Compound or that is simultaneously developed with the
preceding CART Identified Compound with the intent to commercialize both
Compounds. For the purpose of determination of such intent, a subsequent CART
Identified Compound shall be deemed Subsequent Compound if Phase 3 Clinical
Study thereof is started prior to the launch of the preceding CART Identified
Compound.

"SUCCESSFUL SCREENING" when used in conjunction with the phrase "Taisho
Activated Receptor" means that the results of the Screening has been positive
whereby at least one molecule that has been contacted with the Taisho Activated
Receptor reduces the Measured Response of the Taisho Activated Receptor by at
least two (2) standard deviations from the mean response of a screening plate
that includes that compound.

"TAISHO ACTIVATED RECEPTOR" means a [**************] to which the Arena
Activation Technology has been applied.

"TAISHO ACTIVATED RECEPTOR NOTICE" has the same meaning as set forth in Section
3.1 of this Agreement.

"TAISHO CELLS" has the same meaning as set forth in Section 2.1 of this
Agreement.

"TAISHO DEVELOPMENT" as applied to the phrase "CART Identified Compound", means
that Taisho management has approved research and development of a CART
Identified Compound with the intent of developing data based upon such CART
Identified Compound for inclusion within an IND.

"TAISHO'S LICENSEE(S)" means any person or entity, inclusive of Taisho's
Affiliates, to which Taisho has granted sublicenses as referred to in Article V.

"TECHNICAL INFORMATION" means all information, trade secrets, know-how, methods
of manufacture, processes, documents and materials related to Taisho Activated
Receptor(s) and/or Screening Assay(s), and other proprietary information,
whether patentable or unpatentable, related to Taisho Activated Receptor(s)
and/or Screening Assay(s),

                                       4
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

including but not limited to, improvements, that are owned, possessed by, or
licensed to Arena, whether now existing or hereafter developed or acquired
during the term of this Agreement.

"TECHNOLOGY" means Arena Patent Rights and Technical Information.

"TERRITORY" means the world.

"THIRD PARTY" means any person or entity other than Taisho, Taisho's Licensee(s)
and Arena.

                                   ARTICLE II

                    BACKGROUND AND RECEPTOR CLONING RESEARCH

         2.1 BACKGROUND. As of the Effective Date, Taisho has conducted its own
research relating to an Endogenous receptor known as
"[*************************************************************]" and its
subtypes, collectively hereinafter referred to as "[****************]" and
Taisho possesses human cells or cell lines exhibiting [*************] ("Taisho
Cells") and information relating thereto. The [**************] has not been
identified or classified as GPCRs or other receptor subtype. As of the Effective
Date, the Parties each believe that once identified, [**************] may be
identified or classified as GPCRs. Taisho believes that and it is expected that
Arena's technologies, expertise, understanding and experience relating to GPCRs
are valuable such that Taisho has requested that Arena participate with Taisho
in conducting further research relating to the [**************], with the
objective of such further research being the identification, sequencing and
characterization of [**************] from Taisho Cells. As further set forth
herein, Arena and Taisho hereby agree to conduct research relating to the
[**************] for the purpose of obtaining Taisho Activated Receptor(s) under
the terms and conditions of this Agreement.

         2.2 RECEPTOR CLONING RESEARCH. Taisho shall provide to Arena Taisho
Cells and information relating thereto at Taisho's cost and expenses. Arena
shall use Taisho Cells and information relating thereto only for the purposes
set forth and outlined in this Agreement. Subject to the terms and conditions of
this Agreement, Arena agrees to use Best Reasonable Commercial Efforts to (i)
identify and clone receptors from Taisho Cells using Arena Cloning; and (ii)
determine if the receptor(s), if any, identified and cloned from Taisho Cells
correspond to any GPCRs that Arena has at its facility as of the Effective Date.
Arena and Taisho shall jointly develop and mutually agree to a research plan for
such receptor cloning research, which shall be attached to this Agreement as
APPENDIX A.

         2.3 UTILIZATION OF RECEPTOR. To the extent otherwise permitted by law,
Taisho may freely use or utilize, apart from this Agreement, any and all
receptor(s), fragments thereof, peptides and/or nucleotides cloned hereunder by
Arena in accordance with the research program outlined in Section 2.2 of this
Agreement for Taisho's research and

                                       5
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED

<PAGE>

development activities, whether such receptor(s), fragments thereof, peptides or
nucleotides or sequence or function thereof are patentable or not, but only to
the extent that the activities and fees set forth in Articles III and IV are
effectuated by the Parties.

         2.4 NO WARRANTY. ARENA MAKES NO REPRESENTATION THAT ANY ACTIVITY
UNDERTAKEN BY IT IN ACCORDANCE WITH ARTICLE II, OR THAT ANY RECEPTOR(S),
FRAGMENTS(S) THEREOF, PEPTIDES OR NUCLEOTIDES OR SEQUENCE OR FUNCTION THEREFOR
CONDUCTED BY ARENA ON BEHALF OF TAISHO IN ACCORDANCE WITH THIS AGREEMENT AND/OR
USED BY ARENA ON BEHALF OF TAISHO IN ACCORDANCE WITH THIS AGREEMENT AND/OR
TRANSFERRED BY ARENA TO TAISHO IN ACCORDANCE WITH THIS AGREEMENT WILL NOT
INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER PROPRIETARY RIGHT OF ANY
OTHER PERSON. ARENA MAKES NO WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, WITH RESPECT TO
ANY SUCH ACTIVITY OR MATERIAL, AS THE CASE MAY BE.

                                   ARTICLE III

                           ARENA ACTIVATION TECHNOLOGY

         3.1 DEVELOPMENT OF TAISHO ACTIVATED RECEPTOR. Subject to the terms and
conditions of this Agreement, Arena agrees to use Best Reasonable Commercial
Efforts to apply Arena Activation Technology to each subtype of the
[**************] obtained through the research set forth in Section 2.2 of this
Agreement for the purpose of establishing a Taisho Activated Receptor. Upon
creation of each Taisho Activated Receptor, Arena shall provide Notice to Taisho
("Taisho Activated Receptor Notice"), and such Taisho Activated Receptor Notice
shall include data developed by Arena evidencing that the Taisho Activated
Receptor is constitutively active.

         3.2 DEVELOPMENT OF SCREENING ASSAY. Subject to the terms and conditions
of this Agreement, Arena agrees to use Best Reasonable Commercial Efforts to
develop a Screening Assay incorporating each Taisho Activated Receptor. Upon
development of each Screening Assay, Arena shall provide Notice to Taisho
("Screening Assay Notice").

         3.3 TRANSFER OF TAISHO ACTIVATED RECEPTOR AND TECHNICAL INFORMATION.
Subject to the terms and conditions of this Agreement, within thirty (30) days
of each Screening Assay Notice, Arena shall transfer to Taisho the applicable
Taisho Activated Receptor in the form and quantity agreed to in advance by the
Parties, and a copy of all additional Technical Information owned or possessed
by Arena then applicable to such Taisho Activated Receptor and Screening Assay
incorporating such Taisho Activated Receptor. In the event the Successful
Screening using the Taisho Activated Receptor cannot be measured by Taisho in
accordance with the procedures and protocols used by Arena and provided to
Taisho as part of the applicable Technical Information, Arena shall use Best
Reasonable Commercial Efforts to cooperate with Taisho in studying the cause of
such measurement inability. If any defect in the Taisho Activated Receptor or
the Screening Assay transferred by Arena to Taisho is detected and determined to
have been caused by or effected by the activities of Arena, Arena shall at its
costs and expenses, and its sole discretion either repair the defect or transfer
a substitute Taisho Activated Receptor and Screening Assay incorporating such
substituted Taisho Activated Receptor to Taisho.

                                       6
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED

<PAGE>

         3.4 ADDITIONAL SUPPLY. When requested by Taisho in writing, Arena shall
use Best Reasonable Commercial Efforts to supply additional quantity of the
Taisho Activated Receptor within the time period requested by Taisho. If so
agreed by the Parties in writing, Arena shall supply additional Technical
Information owned or possessed by Arena to enable Taisho to reproduce and/or
increase the Taisho Activated Receptor for the purpose of the Screening.

         3.5 TAISHO DILIGENCE. Subject to the terms and conditions of this
Agreement, Taisho agrees to use Best Reasonable Commercial Efforts to conduct
its research and development using Taisho Activated Receptor obtained hereunder
and Screen Assay incorporating such Taisho Activated Receptor.

                                   ARTICLE IV

                          RESEARCH AND DEVELOPMENT FEES

         4.1 RESEARCH AND DEVELOPMENT FEES - [**************] ACTIVITIES. Taisho
shall pay to Arena as follows as research and development fees for Arena's
activities set forth in Article I of this Agreement.

                  (a) CLONING RESEARCH AND DEVELOPMENT FEE: Within thirty (30)
days of the Effective Date, Taisho shall provide Arena with a cloning research
and development fee of [**********************************].

         4.2 RESEARCH AND DEVELOPMENT FEES - ARENA TECHNOLOGY ACTIVITIES. Taisho
shall pay to Arena as follows as research and development fees for Arena's
activities set forth in Article III.

                  (a) Within thirty (30) days after receipt of each Taisho
Activated Receptor Notice, Taisho shall provide Arena with a research and
development fee of [************************************************].

                  (b) Within thirty (30) days after receipt of each Taisho
Activated Receptor and Screening Assay, Taisho shall provide Arena with a
research and development fee of [*********************************************].

                  (c) As to each Taisho Activated Receptor, within thirty (30)
days after the earlier of (i) completion of the Screening by Taisho of
approximately [******] Library Compounds or (ii) completion of the Arena
Screening, Taisho shall provide Arena with a research and development fee of
[************************************************].

         4.3 PAYMENT UNDERSTANDING. Taisho acknowledges and agrees that any
payment due under this Article IV shall be made as required and that once made,
such payment shall be non-refundable and non-creditable. Within 30 days of the
receipt by Arena of each payment, Arena shall provide to Taisho a statement with
supportive documents sufficiently verifying the costs and expenses incurred by
Arena regarding the corresponding research and development activities.

                                       7
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

                                    ARTICLE V

                                  LICENSE GRANT

         5.1 ARENA LICENSE. Subject to receipt by Arena of the payments set
forth in Sections 4.2(a) and 4.2(b) and 4.2(c) of this Agreement, Arena hereby
grants to Taisho the following with respect ONLY to each Taisho Activated
Receptor that is the subject of the Screening Assay Notice:

                  (a) an exclusive right and license under the Technology,
exclusive even as to Arena but subject to the provisions of Section 5.5 and
Article VI, to use, have used, sell, have sold, import, have imported, further
develop, improve and otherwise exploit in any manner the Taisho Activated
Receptor, for the purpose of identification of CART Identified Compound(s) in
the Territory, including the right to sublicense the rights granted to Taisho by
Arena hereunder, and

                  (b) an exclusive right and license under the Technology,
exclusive even as to Arena, to develop, manufacture, have manufactured, promote,
market, sell and distribute CART Identified Compound(s) and/or Drug Product(s)
comprising a CART Identified Compound in the Territory ,including the right to
sublicense the rights granted to Taisho by Arena hereunder.

        5.2 SUBLICENSE. In the event that Taisho sublicenses any right granted
by Arena hereunder, Taisho warrants that it shall notify Arena within one (1)
month of the effective date of any such sublicense agreement; at all times
during the term of this Agreement, Taisho shall have an affirmative obligation
to make any such payments to Arena that Taisho would be required to make to
Arena hereunder, irrespective of the financial situation of any such Taisho's
Licensee(s).

        5.3 IMPROVEMENTS.

                  (a) Taisho shall notify Arena, in writing, of any improvement
discovered or developed by Taisho and/or Taisho's Licensee(s) related to the
Technology.

                  (b) Arena shall notify Taisho, in writing, of any improvement
discovered or developed by Arena related to the Technology within one (1) month
of the discovery or development of such improvement.

                  (c) The obligations of Sections 5.3(a) and (b) of this
Agreement shall be continuing throughout the term of this Agreement. During the
term of this Agreement, Taisho shall be entitled to use any such improvement in
accordance with the provisions of Sections 5.1 and 5.2 of this Agreement.

                  (d) Subject to Section 5.1 and except as specifically provided
for in Section 5.3(e) hereof, Arena shall have a royalty-free, non-exclusive
right and license to use all improvements of Taisho and/or Taisho's Licensee(s)
referred to in Section 5.3(a) hereof and to disclose and sublicense the same to
its licensees, if any.

                  (e) Both Parties acknowledge and agree that Arena has
exclusive ownership of the Technology existing as of the Effective Date and any
improvement thereof hereafter discovered or developed by Arena and that Taisho
has exclusive

                                       8
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED

<PAGE>

ownership of or control over any improvement of the Technology hereafter
discovered or developed by Taisho and/or Taisho's Licensee(s).

         5.4 NO WARRANTY. NEITHER PARTY MAKES ANY REPRESENTATION THAT ANY
[***********] OR TAISHO ACTIVATED RECEPTOR OR SCREENING ASSAY TRANSFERRED BY
ARENA TO TAISHO, OR USED BY ARENA ON BEHALF OF TAISHO IN ACCORDANCE WITH THIS
AGREEMENT, WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER
PROPRIETARY RIGHT OF ANY OTHER PERSON. NEITHER PARTY MAKES ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY,
EXPRESS OR IMPLIED, WITH RESPECT TO ANY [***********] OR TAISHO ACTIVATED
RECEPTOR OR SCREENING assaY, AS THE CASE MAY BE.

         5.5 CONTINUING UTILIZATION FEE.

                  (a) For Taisho Activated Receptor, Taisho shall retain
exclusive rights, for a period Taisho continues the identification and/or
development of CART Identified Compound(s) with its Best Reasonable Commercial
Efforts, in and to such Taisho Activated Receptor when Taisho provides Arena
with a Continuing Utilization Fee of [*****************************************]
before the expiration of [***************************************] from the date
of transfer of such Taisho Activated Receptor to Taisho ("Transfer Anniversary
Date").

                  (b) The Parties acknowledge and understand that once made,
Continuing Utilization Fee shall be non-refundable and non-creditable, and that,
when Taisho does not provide a Continuing Utilization Fee for a Taisho Activated
Receptor, the right and license granted to Taisho under Section 5.1(a) shall be
converted to non-exclusive right and license after the Transfer Anniversary
Date.

                                   ARTICLE VI

                               SCREENING BY ARENA

         6.1 TAISHO SCREENING REQUEST. During the term of this Agreement, Taisho
is entitled to provide Notice to Arena requesting that Arena conduct Screening
efforts for Taisho using a Taisho Activated Receptor, Screening Assay and Arena
Library Compounds ("Screening Request").

         6.2 SCREENING FEE. With each Screening Request made by Taisho under
Section 6.1 of this Agreement, Taisho shall simultaneously provide to Arena a
Screening Fee of [******************************************]. Upon receipt of
such Screening Fee, the following shall apply:

                  (a) For each Taisho Activated Receptor and its corresponding
Screening Assay, Arena, using Best Reasonable Commercial Efforts, shall utilize
the Taisho Activated Receptor and the Screening Assay for Screening using Arena
Library Compounds ("Arena Screening").

                  (b) For each Taisho Activated Receptor subject to Arena
Screening, Arena shall use Best Reasonable Commercial Efforts to identify at
least [*******] CART Identified Compound.

                                       9
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED

<PAGE>

         6.3 TAISHO SCREENING. In the event that Taisho does not provide a
Screening Request to Arena for any, or all, Taisho Activated Receptor(s), Taisho
shall use Best Reasonable Commercial Efforts to conduct Screening of
approximately [******] Library Compounds obtained by Taisho using the Taisho
Activated Receptor. When requested by Taisho in writing, Arena shall use its
Best Reasonable Commercial Efforts to assist Taisho in setting-up the Screening
Assays at Taisho's facility within the time period(s) requested by Taisho.
Taisho agrees to reimburse Arena for the reasonable out-of-pocket costs
associated with the assistance of Taisho with its Screening.

                                   ARTICLE VII

                              CLINICAL DEVELOPMENT
                           OF CART IDENTIFIED COMPOUND

         7.1 For each Taisho Activated Receptor, Taisho shall use Best
Reasonable Commercial Efforts to advance into clinical development at least
[*******] CART Identified Compound. Arena acknowledges and agrees that Taisho
shall have sole discretion to: (i) determine which CART Identified Compound to
develop as a first Drug Product, Back-Up Compound or Subsequent Compound; and
(ii) whether or not to continue development of any CART Identified Compound or
Drug Product.

         7.2 In consideration of the right and license granted to Taisho
hereunder with respect to each Taisho Activated Receptor, Taisho agrees to pay
to Arena the following clinical milestone fees for each CART Identified Compound
as long as this Agreement is in full force and effect. For a CART Identified
Compound, the payment shall be made only at the first occurrence, if any, of a
milestone set forth below as to the Drug Product first applicable to such
milestone that incorporate the CART Identified Compound, regardless of
formulation and/or indication of the Drug Product, PROVIDED, HOWEVER, that the
Parties agree that (i) as long as the development of preceding CART Identified
Compound is being continued, Taisho shall be exempted from the payments of
milestone fees for Back-Up Compound and (ii) any milestone payment made by
Taisho to Arena for the preceding CART Identified Compound may be fully credited
by Taisho against milestone payments for Back-Up Compound that shall become due
by Taisho when: (i) the development of the preceding CART Identified Compound is
discontinued by Taisho and (ii) Back-Up Compound replaces the withdrawn
preceding CART Identified Compound (such replacement shall be notified in
writing to Arena by Taisho).

                  (a) ONE TIME IND DECISION FEE. Taisho shall provide Notice to
Arena of its decision to implement Taisho Development of a CART Identified
Compound. Within thirty (30) days of the date of such Notice, Taisho shall
provide to Arena a One Time IND Decision Fee of [*****************************].

                  (b) ONE TIME IND MILESTONE. Upon the filing of the first IND
in the Territory for a CART Identified Compound, Taisho shall provide to Arena a
One Time IND Milestone of [**********************************] within thirty
(30) days of such filing.

                                       10
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

                  (c) PHASE 2 CLINICAL STUDY MILESTONE. Within thirty (30) days
of the dosing of the first human in a Phase 2 Clinical Study in the Territory of
a Drug Product, Taisho shall provide to Arena a Phase 2 Clinical Study Milestone
of [********************************************************].

                  (d) PHASE 3 CLINICAL STUDY MILESTONE. Within thirty (30) days
of the dosing of the first human in a Phase 3 Clinical Study in the Territory of
a Drug Product, Taisho shall provide to Arena a Phase 3 Clinical Study Milestone
of [**********************************].

         7.3 The Parties acknowledge and agree that the maximum amount that
Taisho would be required to pay to Arena under the provisions of Article VII of
this Agreement as to each CART Identified Compound (inclusive of Back-Up
Compound(s) thereof) would be [***********************************].

         7.4 Notwithstanding anything to the contrary herein contained, payments
of milestone fees for the Subsequent Compound shall only be subject to the
provisions of Article IX of this Agreement, provided, that the provisions of
Article IX of this Agreement shall only apply when, and to the extent that,
Taisho has made all applicable payments for the preceding CART Identified
Compound under Article VII of this Agreement.

         7.5 NEITHER PARTY MAKES ANY REPRESENTATION TO THE OTHER THAT ANY CART
IDENTIFIED COMPOUND OR ANY DRUG PRODUCT WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
TRADEMARK OR OTHER PROPRIETARY RIGHT OF ANY OTHER PERSON. NEITHER PARTY MAKES
ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER
WARRANTY, EXPRESS OR IMPLIED, TO THE OTHER WITH RESPECT TO ANY CART IDENTIFIED
COMPOUND OR ANY DRUG PRODUCT.

                                  ARTICLE VIII

                             MARKETING AUTHORIZATION

         8.1 Taisho shall use Best Reasonable Commercial Efforts to seek
Marketing Authorization for a Drug Product developed using a Taisho Activated
Receptor in the United States, Japan and European County.

         8.2 In consideration of the right and license granted to Taisho
hereunder, Taisho agrees to pay to Arena the following marketing milestone fees
for each CART Identified Compound as long as this Agreement is in full force and
effect. As long as Taisho is using Taisho Activated Receptor, Screening Assay,
CART Identified Compound and/or Drug Candidate, then all such payments shall be
made by Taisho to Arena, even if this Agreement is not in full force and effect
at the time that such payment is due. For a CART Identified Compound, the
payment shall be made only at the first occurrence, if any, of a milestone set
forth below as to the Drug Product first applicable to

                                       11
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED

<PAGE>

such milestone that incorporate the CART Identified Compound, regardless of
formulation and/or indication of the Drug Product.

                 (a) UNITED STATES. For the first Drug Product that has received
Marketing Authorization in the United States, Taisho shall provide Arena with an
approval fee of [************************************] within thirty (30) days
of receipt of notification of such Marketing Authorization.

                 (b) JAPAN. For the first Drug Product that has received
Marketing Authorization in Japan, Taisho shall provide Arena with an approval
fee of [**********************************] within thirty (30) days of receipt
of notification of such Marketing Authorization.

                 (c) EUROPEAN COUNTRY. For the first Drug Product that has
received Marketing Authorization in the first European Country, Taisho shall
provide Arena with an approval fee of [**********************************]
within thirty (30) days of receipt of notification of such Marketing
Authorization.

         8.3 The Parties acknowledge and agree that the maximum amount that
Taisho would be required to pay to Arena under the provisions of Article VIII of
this Agreement as to each CART Identified Compound would be
[************************************].

         8.4 Notwithstanding anything to the contrary herein contained, payments
of marketing milestone fees for the Subsequent Compound shall only be subject to
the provisions of Article IX of this Agreement, provided, that the provisions of
Article IX of this Agreement shall only apply when, and to the extent that,
Taisho has made all applicable payments under Article VIII of this Agreement.

         8.5 DRUG MASTER FILE. Taisho shall be responsible for the preparation
and submission of a drug master file with FDA (as set forth in 21 C.F.R Section
314.420(b)), or any similar file required by any Regulatory Agency. Arena shall,
upon request by Taisho, give all reasonable assistance to Taisho to enable
Taisho to develop, and obtain Marketing Authorization for Drug Product(s).

                                   ARTICLE IX

                              CLINICAL DEVELOPMENT
                             OF SUBSEQUENT COMPOUNDS

         9.1 Arena acknowledges and agrees that Taisho shall have sole
discretion to determine whether or not Taisho shall: (i) develop any Subsequent
Compound, and (ii) to continue development of any Subsequent Compound.

                                       12
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

         9.2 In consideration of the right and license granted to Taisho
hereunder with respect to each Taisho Activated Receptor, Taisho agrees to pay
to Arena the following clinical and marketing milestone fees for each Subsequent
Compound as long as this Agreement is in full force and effect. As long as
Taisho is using Taisho Activated Receptor, Screening Assay, CART Identified
Compound and/or Drug Candidate, then all such payments shall be made by Taisho
to Arena, even if this Agreement is not in full force and effect at the time
that such payment is due. For a Subsequent Compound, the payment shall be made
only at the first occurrence, if any, of a milestone set forth below as to the
Drug Product first applicable to such milestone that incorporate the Subsequent
Compound, regardless of formulation and/or indication of the Drug Product.
Provided, however, the Parties agree that Taisho shall be exempted from the
payments of the following milestone fees until the earlier of (i) Taisho obtains
the Marketing Authorization of the preceding CART Identified Compound or (ii)
Taisho express its intent to commercialize both the preceding CART Identified
Compound and the Subsequent Compound or (iii) the subsequent CART Identified
Compound is deemed the Subsequent Compound but not the Back-Up Compound
according to the definitions thereof, and that if any milestone(s) set forth
below occur during such exemption period, the corresponding milestone fee(s)
shall be paid in a lump sum within thirty (30) days of the end of such exemption
period.

                  (a) REDUCED IND DECISION FEE. Taisho shall provide Notice to
Arena of its decision to implement Taisho Development of a Subsequent Compound.
Within thirty (30) days of the date of such Notice, Taisho shall provide to
Arena a Reduced IND Decision Fee of [*****************************************].

                  (b) REDUCED IND MILESTONE. Upon the filing of an IND in the
Territory for a Subsequent Compound, Taisho shall provide to Arena a Reduced IND
Milestone of [******************************************] within thirty (30)
days of such filing.

                  (c) REDUCED PHASE 2 CLINICAL STUDY MILESTONE. Within thirty
(30) days of the dosing of the first human in a Phase 2 Clinical Study in the
Territory of a Drug Product comprising a Subsequent Compound, Taisho shall
provide to Arena with a Reduced Phase 2 Clinical Study Milestone of
[*************************************************].

                  (d) REDUCED PHASE 3 CLINICAL STUDY MILESTONE. Within thirty
(30) days of the dosing of the first human in a Phase 3 Clinical Study in the
Territory of a Drug Product comprising a Subsequent Compound, Taisho shall
provide to Arena with a Reduced Phase 3 Clinical Study Milestone of
[**********************************].

                                       13
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

                  (e) UNITED STATES. For a Drug Product comprising a Subsequent
Compound that has received Marketing Authorization in the United States, Taisho
shall provide Arena with an approval fee of [**********************************]
within thirty (30) days of receipt of notification of such Marketing
Authorization.

                  (f) JAPAN. For a Drug Product comprising a Subsequent Compound
that has received Marketing Authorization in Japan, Taisho shall provide Arena
with an approval fee of [**********************************] within thirty (30)
days of receipt of notification of such Marketing Authorization.

                  (g) EUROPEAN COUNTRY. For a Drug Product comprising a
Subsequent Compound that has received Marketing Authorization in the first
European Country, Taisho shall provide Arena with an approval fee of
[**********************************] within thirty (30) days of receipt of
notification of such Marketing Authorization.

         9.3 The Parties acknowledge and agree that the maximum amount that
Taisho would be required to pay to Arena under the provisions of Section 9.2 of
this Agreement as to each Subsequent Compound would be [**********************].

         9.4 Arena acknowledges and agrees that in the event that Taisho
discontinues development of a Subsequent Compound prior to the Market
Authorization of the preceding CART Identified Compound, then any milestone
payments otherwise due by Taisho for such Subsequent Compound under this
Agreement shall not be required to be made by Taisho.

         9.5 NEITHER PARTY MAKES ANY REPRESENTATION TO THE OTHER THAT SUBSEQUENT
COMPOUND WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER PROPRIETARY
RIGHT OF ANY OTHER PERSON. NEITHER PARTY MAKES ANY WARRANTY OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED,
TO THE OTHER WITH RESPECT TO ANY SUBSEQUENT COMPOUND.

                                    ARTICLE X

                                ROYALTY PAYMENTS

         10.1 ROYALTY PAYMENT. In consideration of the right and license granted
to Taisho hereunder with respect to each Taisho Activated Receptor, for EACH
Drug Product comprising a CART Identified Compound that has received Marketing
Authorization, Taisho shall provide Arena with a royalty payment based on Annual
Drug Product Revenue as set forth below for a period ending upon the expiration
of twenty (20) years

                                       14
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

from the Effective Date; such royalty payment shall be made within three (3)
months of December 31 for the Annual period to which the Annual Drug Product
Revenue applies:

                  (a) [*****] Percent ([***]) of the portion of Annual Drug
Product Revenue between [*****] and [**************]; and

                  (b) [****] Percent ([***]) of the portion of Annual Drug
Product Revenue between [**************] and [**************]; and

                  (c) [****] Percent ([****]) of the portion of Annual Drug
Product Revenue between [**************] and [**************]; and

                  (d) [*****] Percent ([***]) of the portion of Annual Drug
Product Revenue above [**************].

                  (e) By way of example and not limitation, in the event that
Annual Drug Product Revenue for a Drug Product is [*************], Taisho shall
provide a royalty payment to Arena of [*************], based upon an aggregate
of: [************] (Section 10.1(a) component); [************] (Section 10.1(b)
component); [*************] (Section 10.1(c) component); and [************]
(Section 10.1(d) component).

         10.2 ROYALTY BASED UPON USE OF MATERIAL OBTAINED UNDER ARTICLE II.
Notwithstanding Taisho's agreement to use Best Reasonable Commercial Efforts, in
the event that Taisho fails to identify or develop a CART Identified Compound
but Taisho continues to use any material obtained by Arena under Article II of
this Agreement to develop the compound(s) through its own research activities,
Taisho shall provide Arena with [***] percent ([**]) royalty payment based on
Annual Drug Product Revenue for a period ending upon the expiration of [******]
[(**)] years from the Effective Date; such royalty payment shall be made within
three (3) months of December 31 for the Annual period to which the Annual Drug
Product Revenue applies.

         10.3 AUDIT. In order to verify the completeness and correctness of Drug
Product Revenue, Taisho shall maintain up to date books and records and Arena
shall have the right to conduct, through independent certified public
accountants, at its own cost and at any reasonable time during business hours,
not more often than once each Annual period for not more than three (3) previous
years, and upon reasonable prior Notice, an audit of the accounting procedures
and records of Taisho in computing and calculating royalty payment for Annual
Drug Product Revenue due hereunder. The auditor shall make available to Taisho
and Arena a report enumerating the period covered by the audit of Drug Product
Revenue computed and calculated by the auditor. The costs of such audit shall be
borne by Taisho in the event that a discrepancy of more than five percent (5%)
is discovered through such audit.

                                       15
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

                                   ARTICLE XI

                               PAYMENT ARRANGEMENT

         The Parties acknowledge and agree that any and all payments to be made
by Taisho to Arena under this Agreement are to be (i) in United States Dollars
and (ii) in full as indicated; provided, however, that any income or other tax
which Taisho is required to pay or withhold on behalf of Arena with respect to
payments payable to Arena hereunder shall be deducted from the amounts of such
payments. Taisho agrees to reasonably cooperate with Arena in obtaining a
foreign tax credit in the U.S. with respect to such payment due to Arena.

                                   ARTICLE XII

                                 CONFIDENTIALITY

         12.1 Each Party shall neither disclose to any Third Party any and all
of the information ("Information") disclosed by the other Party hereunder, nor
permit any such Third Party to have access to such Information, nor use such
Information for any purpose other than for purpose of this Agreement, without
the prior written consent of the other Party.

         12.2 The receiving Party's obligations under Section 12.1 hereof shall
not apply, with respect to any of such Information to the extent that the
receiving Party can establish by competent proof that such Information:

                  (a) is published, known publicly, or is already in the public
domain at the time of receipt of it by the receiving Party;

                  (b) is published, becomes known publicly or becomes a part of
the public domain by publication or otherwise after the time of receipt of it by
the receiving Party, except by breach of this Agreement by the receiving Party;

                  (c) is obtained from a Third Party after the receipt of it by
the receiving Party, provided, however, that said Third Party has not obtained
it directly or indirectly from the disclosing Party;

                  (d) is in the receiving Party's possession on the date of the
receipt of it and was not acquired directly or indirectly from the disclosing
Party; or

                  (e) is subsequently developed by the receiving Party
independent of the information received hereunder, as evidenced by competent
written records established by the receiving Party.

         12.3 Notwithstanding anything to the contrary in this Agreement, the
receiving Party shall be entitled to disclose such Information (i) to the extent
required by applicable law or court order provided that the receiving Party
furnishes the disclosing Party with Notice of such request, in advance of any
such disclosure of the Information or (ii) to the

                                       16
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

extent required to comply with the reporting requirements of any governmental
agency, including, but not limited to, the U.S. SEC or NASDAQ Stock market
rules, provided that the receiving Party furnishes the disclosing Party with
Notice of such compliance requirement, in advance of any such disclosure of the
Information, or (iii) to a government agency, regulatory authority, clinical
research organization, clinical investigator or other Third Party to whom
disclosure is necessary for development of the CART Identified Compound in
connection with drug development, approval or registration of the CART
Identified Compound and/or Drug Product.

The foregoing obligations of confidentiality shall survive for five (5) years
after any termination or expiration of this Agreement.

                                  ARTICLE XIII

                       PATENT INFRINGEMENT AND ENFORCEMENT

         13.1 NOTIFICATION OF INFRINGEMENT. Each Party shall promptly provide
Notice to the other of any infringement (of which it becomes aware) of the
intellectual property rights including patent rights on any Taisho Activated
Receptor(s) and/or Screening Assay(s) and/or CART Identified Compound(s) and/or
Drug Product(s) comprising a CART Identified Compound by any Third Party and
shall provide the other with any available evidence of such infringement of
which the Party is aware.

         13.2 SUIT FOR INFRINGEMENT.

                  (a) During the term of this Agreement, Arena shall be
responsible for enforcement of the Arena Patent Rights including, but not
limited to, the bringing of an action for patent infringement, selection of the
forum for such action, and counsel, settlement of any such action, and the costs
devoted to such action. Taisho agrees to provide reasonable assistance except
for financial assistance to Arena in the enforcement of Arena Patent Rights and
Taisho may join such action as initiated by Arena with counsel at its own
expense and seek its own damages and other relief. If, within ninety (90) days
of Taisho's giving Notice to Arena of a Third Party infringement in the
Territory, Arena fails to institute the infringement suit that Taisho reasonably
feels is required, Taisho may institute such infringement proceedings against
said Third Party at its expense and Taisho shall have the right to receive all
the amounts payable by said Third Party as a result of such proceedings.

                  (b) In the event a claim of patent infringement is made
against Taisho by a Third Party in the Territory by reasons of Taisho's
commercial activities hereunder, Taisho and Arena shall meet to analyze the
infringement claim and avoidance of the same. If it is necessary to obtain an
appropriate license from such a Third Party, the Parties shall, in negotiating
such a license, make every efforts to minimize the amount of license fees and/or
royalties payable to such Third Party and (i) in case that such license is
related to Arena Activation Technology, Arena shall be responsible for such
license fees and/or royalties, (ii) in case that such license is related to
[***********] and/or Taisho Activated Receptor and/or Screening Assay, and/or
CART Identified Compound, and/or Drug Product comprising a CART Identified
Compound, Taisho shall be responsible for such license fees and/or royalties.

                                       17
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

                                   ARTICLE XIV

                          REPRESENTATION AND WARRANTIES

         14.1 REPRESENTATIONS AND WARRANTIES OF TAISHO. Taisho represents and
warrants to Arena as follows:

                  (a) The execution and delivery of this Agreement have been
duly and validly authorized, and all necessary action has been taken to make
this Agreement a legal, valid and binding obligation of Taisho enforceable in
accordance with its terms.

                  (b) The execution and delivery of this Agreement and the
performance by Taisho of its obligations hereunder will not contravene or result
in the breach of the Certificate of Incorporation or Bylaws of Taisho or result
in any material breach or violation of or material default under any material
agreement, indenture, license, instrument or understanding or, to the best of
its knowledge, result in breach of any law, rule, regulation, statute, order or
decree, to which Taisho is a party or of which it or any of its property is
subject.

         14.2 REPRESENTATIONS AND WARRANTIES OF ARENA. Arena represents and
warrants to Taisho as follows:

                  (a) The execution and delivery of this Agreement have been
duly and validly authorized, and all necessary action has been taken to make
this Agreement a legal, valid and binding obligation of Arena enforceable in
accordance with its terms.

                  (b) The execution and delivery of this Agreement and the
performance by Arena of its obligations hereunder will not contravene or result
in the breach of the Certificate of Incorporation or Bylaws of Arena or result
in any material breach or violation of or material default under any material
agreement, indenture, license, instrument or understanding or, to the best of
its knowledge, result in breach of any law, rule, regulation, statute, order or
decree, to which Arena is a party or of which it or any of its property is
subject.

                                   ARTICLE XV

                                    INDEMNITY

         15.1 INDEMNIFICATION BY TAISHO. Taisho will indemnify and hold harmless
Arena and its Affiliates, employees, officers, directors, shareholders and
agents (an "Arena Indemnified Party") from and against all liability, loss,
damages, costs and expenses (including reasonable attorneys' fees) which Arena
Indemnified Party may incur, suffer or be required to pay resulting from or
arising in connection with (i) the breach by Taisho of any agreement, covenant,
representation or warranty of Taisho obtained in this Agreement, or (ii)
negligence or omission of Taisho.

         15.2 INDEMNIFICATION BY ARENA. Arena will indemnify and hold harmless
Taisho and its Affiliates, Taisho's Licensees, employees, officers, directors,
shareholders and agents (an "Taisho Indemnified Party") from and against all
liability, loss, damages, costs and expenses (including reasonable attorneys'
fees) which Taisho Indemnified Party may incur, suffer or be required to pay
resulting from or arising in connection with (i) the

                                       18
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

breach by Arena of any agreement, covenant, representation or warranty of Arena
obtained in this Agreement, (ii) negligence or omission of Arena or (iii) the
activities taken by Arena on behalf of Taisho in accordance with the provisions
of Article III of this Agreement.

         15.3 CONDITIONS TO INDEMNIFICATION. The obligations of the indemnifying
Party under Sections 15.1 and 15.2 of this Agreement are conditioned upon the
prompt Notice to the indemnifying Party of any of the aforementioned suits or
claims in writing within fifteen (15) days after receipt of Notice by the
indemnified Party of such suit or claim. The indemnifying Party shall have the
right to assume the defense of any such suit or claim unless, in the reasoned
judgment of the indemnified Party, such suit or claim involves an issue or
matter which could have a materially adverse effect on the business, operations
or assets of the indemnified Party, in which event the indemnified Party may
participate in the defense of such suit or claim at its sole cost and expense.
The provision for indemnification shall be void and there shall be no liability
against an indemnified Party as to any suit or claim for which settlement or
compromise or an offer of settlement or compromise is made without the prior
consent of the indemnifying Party.

                                   ARTICLE XVI

                                   TERMINATION

         16.1 BREACH. Failure by either Party to comply with any of its material
obligations contained in this Agreement shall entitle the other Party to give
Notice to the Party in default specifying the nature of the default and
requiring it to cure such default. If such default is not cured within two (2)
months after receipt of such Notice, the notifying Party shall be entitled,
without prejudice to any of its other rights conferred on it by this Agreement,
to terminate this Agreement and the licenses granted to the breaching Party
hereunder with immediate effect by giving Notice to such termination. The right
of either Party to terminate this Agreement as herein provided shall not be
affected in any way by its waiver of, or failure to take action with respect to,
any previous default.

         16.2 DURATION OF THIS AGREEMENT.

                  (a) This Agreement shall become effective from the Effective
Date and continue to be in effect until expiration of Taisho's obligation of
royalty payment hereunder, if any; such obligation of royalty payment shall be
[******] ([***]) years from the Effective Date. Thereafter, all licenses or
sublicenses granted hereunder shall become fully paid-up irrecoverable license.

                  (b) Either Party shall be entitled to terminate this Agreement
in the event of

                           (1)      insolvency of the other Party or
                                    commencement of bankruptcy proceedings by
                                    such Party; or

                           (2)      dissolution of the other Party by that
                                    Party, or liquidation of such Party by that
                                    Party.

                  (c) The Parties agree that in the event that Taisho
sublicenses any of the rights granted to it under this Agreement to a Third
Party, such sublicense shall include provisions whereby if such sublicensee(s)
becomes insolvent, commences

                                       19
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

bankruptcy proceedings, dissolves, and/or liquidates its assets, any and all
rights granted by Taisho to such sublicensee(s) shall automatically revert
back to Taisho.

         16.3 ACCRUED RIGHTS; SURVIVING OBLIGATIONS. Termination or expiration
of this Agreement for any reason shall be without prejudice to any rights which
shall have accrued to the benefit of either Party prior to such termination or
expiration, nor shall such termination or expiration relieve either Party from
obligations which are expressly indicated to survive termination or expiration
of this Agreement.

                                  ARTICLE XVII

                           RELATIONSHIP OF THE PARTIES

         Nothing in this Agreement is intended or shall be deemed to constitute
a partnership, agency, employer-employee, or joint venture relationship between
the Parties. All activities by each Party hereunder shall be provided as an
independent contractor. No Party shall incur any debts or make any commitments
for the other, except to the extent, if at all, specifically provided herein.

                                  ARTICLE XVIII

                            MISCELLANEOUS PROVISIONS

         18.1 LIMITATIONS ON ASSIGNMENT. Neither this Agreement nor any interest
hereunder shall be assignable or transferable by Arena or Taisho without the
prior written consent of the other Party.

         18.2 FURTHER ACTS AND INSTRUMENTS. Each Party hereto agrees to execute,
acknowledge and deliver such further instruments and to do all such other acts
as may be necessary or appropriate to carry out the purpose and intent of this
Agreement.

         18.3 ENTIRE AGREEMENT. This Agreement constitutes and contains the
entire agreement of the Parties and supersedes any and all prior negotiations,
correspondence, understandings, Letters of Intent and agreements between the
Parties respecting the subject matter hereof. This Agreement may be amended or
modified or one or more provisions hereof waived only by a written instrument
signed by the Parties.

         18.4 SEVERABILITY. If one or more provisions of this Agreement are held
to be unenforceable under applicable law, such provision shall be excluded from
this Agreement and the balance of this Agreement shall be interpreted as if such
provision were so excluded.

         18.5 CAPTIONS. The captions to this Agreement are for convenience only
and are to be of no force or effect in construing and interpreting the
provisions of this Agreement.

         18.6 FORCE MAJEURE. Neither Party shall be liable to the other for loss
or damages, or have any right to terminate this Agreement for any default or
delay, attributable to any act of God, flood, fire, explosion, breakdown or
plant strike, lockout, labor dispute, casualty, accident, war, revolution, civil
commotion, act of a public enemy, blockage, embargo, injunction, law, order,
proclamation, regulation, ordinance, demand

                                       20
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

or requirement of any government or subdivision, authority or representative of
any government, or any other cause beyond the reasonable control of such Party.

         18.7 NO TRADE NAME OR TRADEMARK LICENSE.

                  (a) No right, express or implied, is granted by this Agreement
to Taisho, Taisho collaborators or Taisho's Licensees to use in any manner the
name "Arena," "Arena Pharmaceuticals," "CART" or any trade name or trademark of
Arena in any business dealing which is not directly connected with the
performance of this Agreement; provided, however, that Taisho shall have the
right to use or disclose the name Arena only to the extent and the manner as may
be required by law.

                  (b) No right, express or implied, is granted by this Agreement
to Arena, Arena collaborators or Arena licensees to use in any manner the name
"Taisho" or any trade name or trademark of Taisho in any business dealing which
is not directly connected with the performance of this Agreement; provided,
however, that Arena shall have the right to use or disclose the name Taisho only
to the extent and the manner as may be required by law.

                  (c) During the term of this Agreement, the Parties may issue a
press release regarding the acceptance of this Agreement by the Parties with
prior written consent of the other Party on the contents of such release, which
consent shall not be unreasonably withheld (it is not necessary to obtain the
consent of the other Party for disclosing the information regarding this
Agreement which a Party is required by law to disclose).

         18.8 GOVERNING LAW; CONSENT TO JURISDICTION. This Agreement shall be
governed by and construed under applicable federal law of the United States of
America and the laws of the State of California, excluding any conflict of law
provisions. Each Party hereto hereby voluntarily and irrevocably waives trial by
jury in any action or proceeding brought in connection with this Agreement, any
of the other transaction documents or any of the transactions contemplated
hereby or thereby. Each Party hereby expressly waives any and all rights to
bring any suit, action or other proceeding in or before any court or tribunal
other than arbitration court of the International Chamber of Commerce and
covenants that it shall not seek in any manner to resolve any dispute other than
as set forth in this Section 18.8 or to challenge or set aside any decision,
award or judgment obtained in accordance with the provisions hereof. Each Party
hereby expressly waives any and all objections it may have to venue, including,
without limitation, the inconvenience of such forum, in any of such courts. In
addition, the service of process regarding the arbitration shall be subject to
the rules of arbitration of the International Chamber of Commerce or applicable
laws. The Parties further agree that any dispute resolution initiated by Taisho
under this Section 18.8 shall take place in San Diego, California (U.S.A.) and
that any dispute resolution initiated by Arena under this Section 18.8 shall
take place in Tokyo, JAPAN.

         18.9 EXPENSES. Except as otherwise provided herein, each Party hereto
shall bear its legal and other expenses incurred in connection with the
negotiation, execution, delivery and performance of this Agreement.

         18.10 COUNTERPARTS. This Agreement shall be executed in two
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                       21
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

         18.11 NOTICE. Unless otherwise provided, any Notice required or
permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the Party to be notified or upon
deposit with the registered or certified mail in the country of residence of the
Party giving the Notice, postage prepaid, or upon deposit with an
internationally recognized express courier with proof of delivery, postage
prepaid and addressed to the Party to be notified at the address or addresses
indicated below, or upon the date of fax transmission of such Notice (with proof
of such fax transmission established by the sender's fax receipt) using the fax
numbers listed below, or at such other address or fax number as such Party may
designate by ten (10) days' advance written Notice to the other Party with
copies to be provided as follows:

                                       22
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

                  IF TO ARENA, ADDRESSED TO:
                           Arena Pharmaceuticals, Inc.
                           6166 Nancy Ridge Drive
                           San Diego, CA  92121 USA
                           Attention:  Jack Lief
                                       President & CEO
                           Fax: +1-858-453-7210

                  IF TO TAISHO, ADDRESSED TO:
                          Taisho Pharmaceutical Co., Ltd.
                          24-1, Takata 3-chome,
                          Toshimaku
                          Tokyo 170-8633, JAPAN
                          Attention:   Tetsuya Yamamoto
                                       Group Manager, Business Development Group
                                       Prescription Business Strategy Division,
                          Fax: +81-(0)3-3985-0716

         18.12 SURVIVING RIGHTS AND OBLIGATIONS. The following Articles and
Sections shall survive any termination or expiration of this Agreement: Article
I (Definitions); Article XI (Payment Arrangement); Article XII
(Confidentiality); Article XIII (Patent Infringement and Enforcement); Article
XIV (Representations and Warranties); Article XV (Indemnity); and Sections 2.3,
5.3(d), 5.4, 18.8 and any payment otherwise subsequently or otherwise due under
Articles VII, VIII, IX and/or X. Upon expiration of Taisho royalty obligation
under this Agreement, all licenses and rights granted to Taisho hereunder shall
become fully paid-up irrecoverable license.

         WHEREUPON, the Parties have caused this Agreement to be executed by
their duly authorized agents, as of the dates listed below.

ARENA PHARMACEUTICALS, INC.                 TAISHO PHARMACEUTICAL CO., LTD.

By: /s/ Jack Lief                           By: /s/ Akira Uehara
    -----------------------------               --------------------------------
Name:    Jack Lief                          Name:    Akira Uehara
Title:   President & CEO                    Title:   President

Date:  March 19, 2001                       Date:  March 14, 2001
       --------------------------                -------------------------------

                                       23
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED
<PAGE>

                                   APPENDIX A

Cloning strategy of [**********] receptor cDNA

Cloning of [**********] receptor cDNA will be conducted by following methods at
Arena.

--------------------------------------------------------------------------------

                  [***************] receptor gene cloning

     1. Screen Arena GPCR Database                2. Expression Cloning
       (1)[125I] [*********] binding                 [125I] [**********] binding
       (2)Functional assay by Melanophore

--------------------------------------------------------------------------------

1.       Arena GPCR library

(1)      Arena proprietary GPCRs will be expressed in animal cells such as
         HEK293 or COS cells, and conduct [125I] [**************] and [125I]
         [************] binding.

(2)      Arena proprietary GPCRs will be expressed in frog melanophore cells,
         and responses will be detected by dispersion and aggregation of melanin
         after being exposed to [*****] and [**********].

2.       Expression cloning

                  CDNA library prepared from cell lines exhibiting
                  [125I] [**********] or [125I] [*********] binding activity
                  will be transfected into animal cells such as HEK293 or COS
                  cells, and [************] and [***********] receptor cDNA will
                  be screened by [125I] [**********] and [125I] [************]
                  binding.

                                       24
                                  CONFIDENTIAL
                                   TREATMENT
                                   REQUESTED<PAGE>

                                                                    Exhibit 10.1

                               EMPLOYMENT AGREEMENT

    This Employment Agreement (this "Agreement") is entered into as of
January 12, 2001 by and between Thomas Group, Inc., a Delaware corporation
("Thomas Group" or the "Company") and Mr. John R. Hamann ("Mr. Hamann").

                                    RECITALS

WHEREAS, Mr. Hamann is the President and Chief Executive Officer of Thomas
Group reporting to the Board of Directors and an integral part of its
management who participates in the decision-making process relative to short
and long-term planning and policy for Thomas Group; and

WHEREAS, Thomas Group has determined that it would be in the best interests
of Thomas Group and its stockholders to assure continuity in the management
of Thomas Group's operations by entering into an employment agreement to
retain the services of Mr. Hamann; and

WHEREAS, Thomas Group wishes to assure itself of the continued services of
Mr. Hamann, and Mr. Hamann is willing to be employed by Thomas Group upon the
terms and conditions set forth in this Agreement.

NOW, THEREFORE, in consideration of the premises and the obligations
undertaken by the parties pursuant hereto and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
Thomas Group and Mr. Hamann agree as follows:

1.   DEFINITIONS.  The defined terms used in this Agreement shall have the
meanings ascribed to them in this Section 1.

1.1  BOARD OF DIRECTORS.  "Board" or the "Board of Directors" shall mean the
Board of Directors of Thomas Group or any committee of the Board empowered to
act or make decisions or determinations with respect to this Agreement.

1.2  CAUSE. "Cause" shall mean that, as described below, Mr. Hamann has
engaged in any act of gross misconduct that is injurious to Thomas Group or
its business:

     (a)  Any act by Mr. Hamann of dishonesty, misconduct, fraud,
misappropriation, embezzlement, theft, moral turpitude or the like;

     (b)  Insubordination by Mr. Hamann (e.g., refusal to perform the duties
or responsibilities assigned to him by the Company), unsatisfactory
performance of any such duties or responsibilities, or dereliction of duty; or

     (c)  A material breach of this Agreement or violation of any material
provision of this Agreement.

<PAGE>

1.3  CHANGE IN CONTROL. "Change in Control" shall mean:

     (a)  if any individual, entity or group (within the meaning of Section
13(d)(3) or 14(d)(2) of the Exchange Act) (a "Person") is or becomes the
"beneficial owner" (as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of securities of the Company representing 40 percent
or more of the combined voting power of the Company's then outstanding
securities; or

     (b)  if individuals who, as of the date hereof, constitute the Board
(the "Incumbent Board") cease for any reason to constitute more than 50
percent of the members of the Board; provided, however, that any individual
becoming a director subsequent to the date hereof whose election or
nomination for election by Thomas Group's stockholders was approved by a vote
of at least two-thirds of the directors then constituting the Incumbent
Board, shall be considered as though such individual were a member of the
Incumbent Board; or

     (c)  if stockholders of the Company approve a merger, consolidation, or
reorganization of the Company with or into another corporation or other legal
person, and as a result of such merger, consolidation or reorganization less
than 51% of the combined voting power of the then outstanding securities of
the remaining corporation or legal person or its ultimate parent immediately
after such transaction is owned by persons who were stockholders of the
Company immediately prior to such merger, consolidation, or reorganization; or

     (d)  if stockholders of the Company approve a sale or disposition of all
or substantially all of the Company's assets to any other corporation or
other legal person, and as a result of such sale less than 51% of the
combined voting power of the then outstanding securities of such corporation
or legal person or its ultimate parent immediately after such transaction is
owned by persons who were stockholders of the Company immediately prior to
such sale or disposition; or

     (e)  if stockholders of the Company approve a plan of liquidation or
dissolution of the Company; or

     (f)  any occurrence that would be required to be reported in response to
Item 6(e) of Schedule 14A of Regulation 14A or any successor rule or
regulation promulgated under the Exchange Act.

1.4  COMMON STOCK. "Common Stock" shall mean the common stock of Thomas
Group, par value $.01 per share.

1.5  DISABILITY. "Disability" shall mean the inability of Mr. Hamann to
perform his material managerial duties and responsibilities as contemplated
under Section 2 during his employment with Thomas Group, with or without a
reasonable accommodation, for a consecutive period of three (3) months or a
non-consecutive period of six (6) months within any twelve- (12) month
period.  The Company will comply with the requirements of the Americans with
Disabilities Act with respect to attempting to reach a reasonable
accommodation. The existence of Disability and the date of commencement of
Disability shall be determined in accordance with Section 5.1(e).

                                       2
<PAGE>

1.6  GOOD REASON. "Good Reason" shall mean Mr. Hamann's decision to terminate
his employment under this Agreement if Thomas Group or any successor commits
any material breach of this Agreement, or the diminishment of Mr. Hamann's
base salary below $425,000, or the diminishment in Mr. Hamann's work
responsibilities below those of President and Chief Executive Officer.

1.7  TERM OF EMPLOYMENT. "Term of Employment" shall mean the period of time
commencing January 12, 2001 and continuing until January 12, 2004, during
which Mr. Hamann is to remain in the employ of Thomas Group; PROVIDED,
HOWEVER, that Mr. Hamann and Thomas Group can agree, in writing, to extend
the Term of Employment.

2.    EMPLOYMENT.  Thomas Group employs Mr. Hamann and Mr. Hamann accepts
employment by Thomas Group as President and Chief Executive Officer of Thomas
Group for the Term of Employment on the terms and conditions and for the
compensation set forth in this Agreement.  Subject to the authority of the
Board of Directors, Mr. Hamann shall be responsible for the overall
operations of Thomas Group in the ordinary course of its business with all
such powers as may be reasonably incident to such responsibilities as its
President and Chief Executive Officer.  Mr. Hamann shall devote his full time
and effort to the discharge of his duties as Thomas Group's President and
Chief Executive Officer.

3.    COMPENSATION AND BENEFITS DURING THE TERM OF EMPLOYMENT.

3.1   BASE COMPENSATION.  Mr. Hamann shall receive base compensation ("Base
Compensation") in the amount determined by the Nominating, Corporate
Governance and Compensation Committee of the Board of Directors (the
"Compensation Committee").  The amount of Mr. Hamann's Base Compensation
shall initially be $425,000 annually and shall be reviewed annually by the
Compensation Committee, no later than March 30 of each year.  Thomas Group
shall pay Base Compensation to Mr. Hamann in equal monthly installments.

3.2   INCENTIVE COMPENSATION ARRANGEMENT.  In further consideration of Mr.
Hamann's performance of services under Section 2, Thomas Group agrees to
compensate Mr. Hamann under the incentive compensation arrangement set forth
in the document entitled "Incentive Compensation for John R. Hamann."  The
computation of annual incentive compensation will be based upon the audited
financial results of Thomas Group.  Thomas Group shall pay the incentive
compensation to Mr. Hamann within fifteen (15) days following completion of
the audit of Thomas Group's financial statements by the Company's certified
public accountants, and no later than April 15 of each year.  Except as
contemplated by Exhibit I, Mr. Hamann must be on the active payroll at the
time an incentive award is paid, in order to be eligible to receive an award.

3.3   TRAVEL COSTS.  Thomas Group shall reimburse Mr. Hamann for all
reasonable travel costs incurred by Mr. Hamann in connection with Thomas
Group's business, together with all other reasonable business expenses of Mr.
Hamann in performing his duties.

                                       3
<PAGE>

3.4   AUTOMOBILE EXPENSES.  Thomas Group shall provide Mr. Hamann a monthly
car allowance in the amount of $1,400.

3.5   INSURANCE; BENEFIT PLAN PARTICIPATION.  Mr. Hamann shall be entitled to
participate in Thomas Group's 401(k) and deferred compensation plans, subject
to the terms and conditions of such plans.  Thomas Group also shall provide
medical, disability and life insurance coverage to Mr. Hamann on the terms
and conditions of each of the plans Thomas Group maintains.  Thomas Group
will purchase term insurance covering Mr. Hamann, payable to Mr. Hamann's
designated beneficiaries (or to his estate) in the case of death while in the
employment of Thomas Group.  Such term insurance will have a face value of $1
million and Thomas Group will pay the annual premiums while Mr. Hamann is in
the employ of Thomas Group.

3.6   STOCK OPTIONS. During the Term of Employment, Thomas Group will grant
Mr. Hamann options to purchase 300,000 shares of Thomas Group Common Stock.
Such options will be granted in three tranches: 100,000 on January 12, 2001,
an additional 100,000 on January 12, 2001, and an additional 100,000 on
January 12, 2001.  Each grant will have a one-year vesting period.  At the
discretion of the Compensation Committee, additional options may be granted
on each anniversary date of this Agreement.  The exercise price for each
option shall be 100% of the fair market value of the Common Stock on the date
of grant.

3.7   RELOCATION COSTS.  Thomas Group will reimburse Mr. Hamann for the
direct costs of moving Mr. Hamann and his family to Dallas, Texas.  Such
reimbursement will be grossed up for taxes.  Mr. Hamann will receive a
$500,000 loan from the Company, documented by a promissory note.  The Company
will pay interest on the promissory note, grossed up for taxes, until Mr.
Hamann sells his residence in Florida, at which time Mr. Hamann will repay
the promissory note in full.

The Company will pay all costs of Mr. Hamann's residence in Florida
(mortgage, taxes, utilities, insurance, and maintenance), grossed up for
taxes, once Mr. Hamann closes on his residence in Texas and until Mr. Hamann
sells his residence in Florida.  Mr. Hamann agrees to use all reasonable
efforts to sell his residence in Florida.

The Company will pay all closing costs of buying and selling Mr. Hamann's
Texas and Florida residences, grossed up for taxes, and will pay customary
points for the purchase of the Texas residence.

4.   TERM OF THE AGREEMENT.  The term of this Agreement, unless terminated
sooner pursuant to Section 5, shall be for the Term of Employment.

5.   TERMINATION; DISABILITY; DEATH; CHANGE IN CONTROL.

5.1  BASIS.  Mr. Hamann's employment under this Agreement may be terminated
as described in this Section 5.1.  In the event that Mr. Hamann's employment
is terminated, Mr. Hamann shall be entitled to receive the benefits described
in Section5.2 that correspond with the manner of such termination.

                                       4
<PAGE>

(a)  TERMINATION WITHOUT CAUSE.  Thomas Group may terminate Mr. Hamann's
employment without Cause by written notice to Mr. Hamann to that effect.
Unless otherwise specified in the notice, such termination shall be effective
immediately.

(b)  TERMINATION WITH CAUSE.  Thomas Group may terminate the employment of
Mr. Hamann for Cause by written notice to Mr. Hamann to that effect.  Unless
otherwise specified in the notice, such termination shall be effective
immediately.

(c)  GOOD REASON.  Upon the occurrence of an event constituting Good Reason
as described in Section 1.6, Mr. Hamann may terminate his employment for Good
Reason within 30 days thereafter upon written notice to Thomas Group to that
effect.  If the effect of the occurrence of the event described in Section
1.6 may be cured, Thomas Group shall have the opportunity to cure any such
effect for a period of 30 days following receipt of Mr. Hamann's termination
notice.  The right of Mr. Hamann to terminate his employment for Good Reason
under this Section 5.1(c) shall not limit Thomas Group's ability to terminate
Mr. Hamann for Cause under Section 5.1(b), if Cause is determined to exist
prior to the time Mr. Hamann delivers to Thomas Group his written notice of
termination for Good Reason.

(d)  WITHOUT GOOD REASON.  Mr. Hamann may voluntarily terminate his
employment without Good Reason upon written notice to Thomas Group to that
effect.

(e)  DISABILITY.  Mr. Hamann or Thomas Group may terminate Mr. Hamann's
employment by reason of Disability, immediately upon written notice to the
other party to that effect.  If the parties are unable to agree as to the
existence of Disability or as to the date of commencement of Disability, each
of Mr. Hamann and Thomas Group shall select a physician licensed to practice
medicine in the United States and the determination as to any such question
shall be made by such physicians; PROVIDED, HOWEVER, that if such two
physicians are unable to agree, they shall mutually select a third physician
licensed to practice medicine in the United States and the determination as
to any such question shall be made by a majority of such physicians.  Any
determination made by such physicians in accordance with the provisions of
the immediately foregoing sentence shall be final and binding on the parties.
 Mr. Hamann agrees to submit to any and all reasonable medical examinations
or procedures and to execute and deliver any and all consents to release of
medical information and records or otherwise as shall be reasonably required
by any of the physicians selected in accordance with this Section 5.1(e).
Unless otherwise specified in the notice, such termination shall be effective
immediately.

(f)  DEATH.  This Employment Agreement shall automatically terminate as of
the date of Mr. Hamann's death.

                                       5
<PAGE>

(g)  CHANGE IN CONTROL.  Following a Change in Control, Mr. Hamann shall be
required to continue his employment under this Agreement for 90 days after
the date of such Change in Control, unless his employment is terminated
sooner by Thomas Group as set forth in Section 5.1(h).  In the event that Mr.
Hamann decides to resign or otherwise voluntarily terminate his employment
following the occurrence of a Change in Control, Mr. Hamann may do so by
giving written notice to Thomas Group to that effect on or before 90 days
after the occurrence of the Change in Control.  If Mr. Hamann does not give
such notice to Thomas Group, this Agreement will remain in effect; PROVIDED,
HOWEVER, that the failure of Mr. Hamann to terminate this Agreement following
the occurrence of a Change in Control shall not be deemed a waiver of Mr.
Hamann's right to terminate his employment upon a subsequent occurrence of a
Change in Control in accordance with the terms of this subsection.

(h)  Notwithstanding that Employee has given notice of termination pursuant
to Section 5.1(g), Thomas Group may, in its sole discretion, thereafter
require Mr. Hamann to terminate his employment prior to the expiration of the
applicable notice period.

5.2  BENEFITS UPON TERMINATION.  Mr. Hamann shall receive the benefits
described in the subsection below that corresponds with the manner of
termination of Mr. Hamann's employment under Section 5.1.

(a)  WITHOUT CAUSE.  In the event Thomas Group terminates Mr. Hamann's
employment without Cause, Mr. Hamann shall be entitled to the payments and
benefits set forth on Exhibit I.

(b)  WITH CAUSE.  In the event Mr. Hamann's employment is terminated with
Cause, no further payments or benefits shall be paid or provided by Thomas
Group to Mr. Hamann except for reimbursement for expenses incurred prior to
the date of termination, or the payment of incentive compensation that has
become due and payable to Mr. Hamann on or before the date of such
termination under Section 3.2.  In addition, Mr. Hamann shall be entitled to
exercise any vested but unexercised stock options for a period of 90 days
following the effective date of the termination for Cause, and if any such
options remain unexercised upon the expiration of such 90-day period, they
shall be determined forfeited.

(c)  GOOD REASON.  In the event Mr. Hamann terminates his employment for Good
Reason, Mr. Hamann shall be entitled to the payments and benefits set forth
on ExhibitI.

(d)  WITHOUT GOOD REASON.  In the event Mr. Hamann terminates his employment
without Good Reason pursuant to Section 5.1(d), Mr. Hamann shall be entitled
to the benefits or payments provided for in Section 5.2(b).

(e)  DISABILITY.  In the event that Mr. Hamann's employment is terminated by
reason of Disability, Mr. Hamann shall be entitled to the payments and
benefits set forth on ExhibitI.  Additionally, Mr. Hamann or the estate,
beneficiary or legal representative of Mr. Hamann shall be entitled to
disability benefits available under benefit plans maintained by the Company
at the time of such Disability.

                                       6
<PAGE>

(f)  DEATH.  In the event Mr. Hamann's employment is terminated by reason of
his death, Thomas Group shall not be required to make any payments or provide
any benefits, except for (a) reimbursement for expenses incurred prior to
such termination date and (b) payment of incentive compensation through such
termination date as provided in Section 3.2, PROVIDED, HOWEVER, that nothing
contained herein shall limit or diminish any rights of Mr. Hamann's estate or
any other person to payments under any life insurance policy maintained by
Thomas Group for the benefit of Mr. Hamann or his beneficiaries or any
health, disability or other benefit plan provided pursuant to Section 3.5, in
each case in accordance with the terms of such plan.  If Mr. Hamann's
employment is terminated by reason of his death, the benefits provided under
this Section 5.2(f) shall be paid to the beneficiary or beneficiaries
designated in writing by Mr. Hamann and delivered to an officer/manager of
Thomas Group; however, if no such beneficiary designation is made by Mr.
Hamann during his lifetime, the benefits hereunder shall be paid to his
estate.  In addition, Mr. Hamann's estate shall be entitled to exercise any
vested but unexercised stock options for a period of 180 days following the
date of Mr. Hamann's death, and if any such options remain unexercised upon
the expiration of such 180-day period, they shall be determined forfeited.

(g)  CHANGE IN CONTROL.  In the event Mr. Hamann's employment is terminated
as provided in Section 5.1(g) following the occurrence of a Change in
Control, Mr. Hamann shall be entitled to the payments and benefits provided
in Exhibit I.

6.   RESTRICTIVE COVENANTS; WORK PRODUCT; CONFIDENTIALITY.

6.1  RESTRICTIVE COVENANTS

Without the prior written consent of Thomas Group, Mr. Hamann shall not:

(a)  During employment with Thomas Group and for a period of two (2) years
following termination of employment, engage in or perform services for a
Competing Business.  For purposes of this Agreement a "Competing Business" is
one which provides the same or substantially similar products and services as
those provided by Thomas Group during Mr. Hamann's employment, including but
not limited to management consulting services to improve the cycle time of
business processes of any business organization.  This restriction is limited
to the geographic area(s) in which Mr. Hamann performed services for Thomas
Group, including but not limited to, the area within a 50-mile radius of any
office or facility of Thomas Group.

(b)  During employment with Thomas Group and for a period of two (2) years
following the termination of employment, solicit business from, attempt to do
business with, or do business with any client of Thomas Group with whom
Thomas Group did business within the preceding 12 months, and with whomMr.
Hamann became acquainted as a result of his employment with Thomas Group.
This restriction applies also to prospective clients of Thomas Group for whom
Thomas Group has performed an analysis or assessment.  This restriction
applies only to business that is in the scope of a Competing Business as
defined in this Agreement.  The geographic area for purposes of this
restriction is the area where the client/prospective client is located and/or
does business.

                                       7
<PAGE>

(c)  For a period of two (2) years following the termination of employment,
solicit, induce or attempt to solicit or induce any employee of Thomas Group
to terminate his/her employment with Thomas Group and/or accept employment
elsewhere.

Mr. Hamann agrees that the scope of the restrictions in this section is
reasonable and necessary to protect Thomas Group's business goodwill,
Confidential Information and other legitimate business interests.

6.2  RIGHT TO WORK PRODUCT; CONFIDENTIALITY.

(a)  Thomas Group and Mr. Hamann each acknowledge that performance of this
Agreement may result in the discovery, creation or development of inventions,
combinations, methods, formulae, techniques, processes, improvements,
software designs, computer programs, strategies, specific computer-related
know-how, course materials, seminar materials, computer models, customer
lists, data and original works of authorship (collectively, the "Work
Product").  Mr. Hamann agrees that he will promptly and fully disclose to
Thomas Group any and all Work Product generated, conceived, reduced to
practice or learned by him, either solely or jointly with others, during his
employment with Thomas Group, which in any way relates to the business of
Thomas Group.  Mr. Hamann further agrees that neither he, nor any party
claiming through him will, other than in the performance of this Agreement,
make use of or disclose to others any proprietary information relating to the
Work Product.

(b)  Mr. Hamann agrees that, whether or not the services performed by Mr.
Hamann under this Agreement are considered works made for hire or an
employment to invent, all Work Product discovered, created or developed under
this Agreement shall be and remain the sole property of Thomas Group and its
assigns.  Mr. Hamann agrees that Thomas Group shall have all copyright and
patent rights with respect to any Work Product discovered, created, or
developed under this Agreement without regard to the origin of the Work
Product.

                                       8
<PAGE>

(c)  Thomas Group agrees that it will provide Mr. Hamann with specialized
knowledge and training regarding the business in which Thomas Group is
involved, and will provide Mr. Hamann with initial and ongoing confidential
information and trade secrets of Thomas Group ("Confidential Information").
For purposes of this Agreement, Confidential Information includes:
information regarding the use and application of Total Cycle Time
methodologies and other information and concepts developed by Thomas Group to
improve the business processes of corporations and other organizations;
software or other technology developed by Thomas Group and any research data
or other documentation related to the development of such
software/technology; client lists and prospects lists developed by Thomas
Group; information regarding Thomas Group's clients which Mr. Hamann acquires
as a result of employment with Thomas Group, including client contracts, work
performed for clients, client contacts, client requirements and needs, data
used by Thomas Group to formulate client bids, client financial information,
and other information regarding the client's business; information related to
Thomas Group's business, including but not limited to marketing strategies
and plans, sales procedures, operating policies and procedures, pricing and
pricing strategies, business plans, sales, profits, and other business and
financial information of the Company; training materials developed by and
utilized by Thomas Group; and any other information which Mr. Hamann acquired
as a result of his employment with Thomas Group and which Mr. Hamann has a
reasonable basis to believe Thomas Group would not want disclosed to a
business competitor or to the general public.

(d)  Mr. Hamann understands and acknowledges that such Confidential
Information gives Thomas Group a competitive advantage over others who do not
have this information, and that Thomas Group would be harmed if the
Confidential Information were disclosed.  Mr. Hamann agrees that he will hold
all Confidential Information in trust and will not use the information for
any purpose other than the benefit of Thomas Group, or disclose to any person
or entity any Confidential Information except as necessary during Mr.
Hamann's employment with Thomas Group to perform services on behalf of Thomas
Group.  Mr. Hamann will also take reasonable steps to safeguard such
Confidential Information and prevent its disclosure to unauthorized persons.

                                       9
<PAGE>

7.   GENERAL PROVISIONS.

7.1  NOTICES.  All notices, requests, demands, or other communications with
respect to this Agreement shall be in writing and shall be personally
delivered, sent via telecopy, or mailed, postage prepaid, certified or
registered mail, or delivered by a nationally recognized express courier
service, charges prepaid, to the following addresses (or such other addresses
as the parties may specify from time to time in accordance with this Section
7.1):

Mr. Hamann:      John R. Hamann
                 4421 Caesar Lane
                 Irving, TX  75038

Thomas Group:    Thomas Group, Inc.
                 5215 North O'Connor Boulevard
                 Suite 2500
                 Irving, TX  75039

Any such notice shall, when sent in accordance with the preceding sentence,
be deemed to have been given and received (i) on the day personally delivered
or sent via telecopy, (ii) on the third day following the date mailed, or
(iii) 24 hours after shipment by such courier service.

7.2  ENTIRE AGREEMENT.  This Agreement, together with the exhibits hereto,
supersedes any and all other agreements, either oral or written, between the
parties hereto with respect to the employment of Mr. Hamann by Thomas Group
and contains all of the covenants and agreements between the parties with
respect to such employment.  Any modification of this Agreement will be
effective only if it is in writing signed by each of the parties hereto.

7.3  GOVERNING LAW.  This Agreement shall be governed by and construed in
accordance with the laws of the State of Texas.

                                       10
<PAGE>

7.4  RESOLUTION OF CERTAIN CONTROVERSIES. In the event of a breach of this
Agreement by Mr. Hamann, Thomas Group shall be entitled to all appropriate
equitable and legal relief, including, but not limited to: (a) injunction to
enforce this Agreement or prevent conduct in violation of this Agreement; (b)
damages incurred by Thomas Group as a result of the breach; and (c)attorneys'
fees and costs incurred by Thomas Group in enforcing the terms of this
Agreement.  Additionally, any period or periods of breach of Section 6 of
this Agreement shall not count toward the restrictive period, but shall
instead be added to the restrictive period.  In the event of any controversy
or claim arising out of or related to the provisions concerning the use and
protection of Confidential Information or the restrictive covenants, Thomas
Group shall be entitled to seek equitable and other relief.  In the event of
any controversy or claim arising out of or related to the other provisions of
this Agreement, the parties agree first to try in good faith to settle the
dispute by non-binding mediation administered by the American Arbitration
Association under its Commercial Mediation Rules.  In the event that
mediation does not resolve the dispute, such dispute shall be settled
exclusively by arbitration in accordance with the Commercial Arbitration
Rules of the American Arbitration Association in Dallas, Texas, and judgment
may be entered in any court having jurisdiction thereof.  Each party is
responsible for its own attorneys' fees and costs of preparing for and
presenting its case at the arbitration.  However, Thomas Group shall pay the
fee of the American Arbitration Association, the arbitration panel's fee, and
costs associated with the facilities for the arbitration, and the arbitration
panel shall not apportion these costs.

7.5  PARTIAL INVALIDITY.  In the event any court of competent jurisdiction
holds any provision of this Agreement to be invalid, the remaining provisions
shall not be affected or invalidated and shall remain in full force and
effect.

7.6  REFORMATION.  In the event any court of competent jurisdiction holds any
restrictions in this Agreement to be unreasonable and/or unenforceable as
written, the court may reform the Agreement to make it enforceable, and the
Agreement shall remain in full force and effect as reformed by the court.

7.7  BINDING EFFECT.  This Agreement is for the sole and exclusive benefit
of, and shall be binding upon Employee, Thomas Group and any subsidiaries,
affiliated companies, successors or assigns of Thomas Group.  This Agreement
is not assignable by Employee.

                                       11
<PAGE>

7.8  AMENDMENTS.  Amendments to any section of this Agreement shall not be
effective unless agreed to in writing by the parties to this Agreement.  This
Agreement, including this provision against oral modification, shall not be
amended, modified or terminated except in a writing signed by each of the
parties to this Agreement, and no waiver of any provision of this Agreement
shall be effective unless in a writing duly signed by the party sought to be
bound.

7.9  SURVIVAL OF PROVISIONS.  The covenants and obligations in Sections 6 and
7 of this Agreement shall survive and continue in effect following the
termination of this Agreement.

7.10 CERTAIN TAX PROVISIONS.  Mr. Hamann acknowledges and agrees that all
payments and benefits which are required by applicable federal, state or
local laws to be subject to withholding for income taxes, shall be so subject.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective
as of the date first above written.

                                  MR. HAMANN:

                                  ---------------------------------------------
                                  John R. Hamann, individually

                                  THOMAS GROUP, INC.

                                  By:
                                     ------------------------------------------
                                  Name:   James E. Dykes
                                  Title:  Chairman, Nominating, Corporate
                                          Governance and Compensation Committee

                                       12
<PAGE>

                                    EXHIBIT I

                            SEVERANCE BENEFIT PAYMENTS

TERMINATION DURING THE FIRST 12 MONTHS OF THIS AGREEMENT:

1.  A lump sum payment in cash, not later than 20 days after the termination
of Mr. Hamann's employment, in an amount equal to the total of (a) unpaid
base compensation through January 12, 2004 plus (b) unpaid incentive
compensation for fiscal years 2001, 2002 and 2003 at the target incentive
compensation of 50% of base compensation.

2.  The unvested portion of stock options granted to Mr. Hamann shall become
fully vested and immediately exercisable on the effective date of such
termination and shall be exercisable for the maximum period specified in such
options.

3.  The Company will reimburse Mr. Hamann for the direct costs of moving Mr.
Hamann and his family to another location within the continental United
States.  Such reimbursement will be grossed up for taxes.

                                     *****

TERMINATION DURING THE FINAL 18 MONTHS OF THIS AGREEMENT:

1.  A lump sum payment in cash, not later than 20 days after the termination
of Mr. Hamann's employment, in an amount equal to the total of (a) 1.5 times
Mr. Hamann's then-current base compensation plus (b) 18 months of incentive
compensation at the target incentive compensation of 50% of base compensation.

2.  The unvested portion of stock options granted to Mr. Hamann shall become
fully vested and immediately exercisable on the effective date of such
termination and shall be exercisable for the maximum period specified in such
options.

                                       13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]